Janet Lynch Lambert – VJRegenMed

Looking forward to Advanced Therapies Week 2022

Simon Ng — Mon, 31 Jan 2022 17:59:07 +0000

Janet Lynch Lambert, CEO, Alliance for Regenerative Medicine, Washington, D.C., shares her excitement towards meeting colleagues and learning about the latest scientific advances at the Advanced Therapies Week 2022, in particular in in vivo gene editing and in vivo chimeric antigen receptor (CAR) T-cells. This interview took place at Advanced Therapies Week 2022.

A 2022 update of the Alliance for Regenerative Medicine

Simon Ng — Fri, 28 Jan 2022 12:04:07 +0000

Janet Lynch Lambert, CEO, Alliance for Regenerative Medicine, Washington, D.C., comments on recent achievements and priorities for ARM in 2022. The past year has seen ARM expand in terms of partnerships with patient advocacy groups and research institutions and Ms Lambert additionally emphasizes the importance of ARM within the cell and gene therapy sector in terms influencing regulatory and reimbursement policies. This interview took place at Advanced Therapies Week 2022.

Addressing issues in the clinical translation of cell & gene therapies

Simon Ng — Thu, 27 Jan 2022 18:16:19 +0000

Janet Lynch Lambert, CEO, Alliance for Regenerative Medicine, Washington, D.C., discusses remaining hurdles that need to be overcome in cell and gene therapies. Dosing as well as delivery strategies need to be optimized, and issues remain within the regulatory and Chemistry, Manufacturing and Controls (CMC) framework. Health Technology Assessments (HTA), GMO regulations, and fundraising methods have additionally restricted the development of gene therapies in Europe. Ms Lambert additionally highlights the need for innovative reimbursement models to ensure affordable treatment for patients. This interview took place at Advanced Therapies Week 2022.

The GROW Internship Program: Improving the representation of Black employees within the CGT field

Simon Ng — Thu, 27 Jan 2022 18:16:18 +0000

Janet Lynch Lambert, CEO, Alliance for Regenerative Medicine, Washington, D.C., talks on the goals and current status of ARM’s GROW Internship Program which aims to address the underrepresentation of Black employees within the cell and gene therapy (CGT) sector. This internship program provides paid summer internships to Black undergraduate and postgraduate students in some of their member organizations. Whilst many of these internships are in STEM, there are also opportunities in patient advocacy, operations and supply management. 17 students have so far been matched and three have been hired full-time by their internship employer. This number will hopefully increase over the years to build a community of GROW interns. This interview took place at Advanced Therapies Week 2022.